

ANNOUNCEMENT OF ALLOTMENT RESULTS

SUMMARY

Offer Price

The Offer Price is HK\$18.60 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%).

Net Proceeds from the Global Offering

- Based on the Offer Price of HK\$18.60 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of underwriting commissions and other estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$120.4 million (assuming the Over-allotment Option is not exercised). The Company intends to apply such net proceeds from the Global Offering in the manner as set out in the paragraph headed “Net Proceeds from the Global Offering” in this announcement.
- If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$26.5 million for 1,487,800 additional Offer Shares to be issued and allotted upon the exercise of the Over-allotment Option, which will be allocated on a pro rata basis according to the use of proceeds as set out in the paragraph headed “Net Proceeds from the Global Offering” in this announcement.

Applications and Indications of Interest Received under the Hong Kong Public Offering

- The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been significantly over-subscribed. A total of 7,588 valid applications have been received under the Hong Kong Public Offering through the **HK eIPO White Form** service and the **CCASS EIPO** service for a total of 8,203,200 Hong Kong Offer Shares, representing approximately 8.27 times of the total number of 992,000 Offer Shares initially available for subscription under the Hong Kong Public Offering.
- As the over-subscription in the Hong Kong Public Offering is less than 15 times, no reallocation of Offer Shares as described in the paragraph headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus has been effected from the International Offering to the Hong Kong Public Offering.
- The final number of Offer Shares under the Hong Kong Public Offering is 992,000 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and being allocated to 2,100 successful applicants under the Hong Kong Public Offering, among which 1,925 applicants (representing approximately 91.67% of the 2,100 Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering) have been allocated one board lot of Offer Shares totalling 385,000 Shares (representing approximately 38.81% of the total Offer Shares under the Hong Kong Public Offering).

International Offering

- The Offer Shares initially offered under the International Offering were slightly over-subscribed. A total of 12,591,107 Offer Shares under the International Offering have been subscribed, representing approximately 1.41 times of the total number of 8,927,400 Offer Shares initially available under the International Offering. The final number of Offer Shares allocated to the places under the International Offering is 8,927,400 Offer Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).
- There has been an over-allocation of 1,487,800 Offer Shares in the International Offering and there are a total of 124 places under the International Offering, among which (i) 118 places have been allotted five or fewer board lots of Offer Shares totalling 38,400 Offer Shares; (ii) 118 places have been allotted four or fewer board lots of Offer Shares totalling 38,400 Offer Shares; (iii) 110 places have been allotted three or fewer board lots of Offer Shares totalling 32,000 Offer Shares; (iv) 92 places have been allotted two or fewer board lots of Offer Shares totalling 21,200 Offer Shares; and (v) 78 places have been allotted one board lot of Offer Shares totalling 15,600 Offer Shares.
- The International Offering is in compliance with the Placing Guidelines for Equity Securities in Appendix 6 to the Listing Rules (the “**Placing Guidelines**”). None of the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters, the Capital Market Intermediaries and their respective affiliated companies and connected clients of the lead broker or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Shares for its own benefit under the Global Offering.
- The Directors confirm that, to the best of their knowledge and information, no Offer Shares under the International Offering placed by or through the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters or the Capital Market Intermediaries under the Global Offering have been placed with any core connected person (as defined in the Listing Rules) of the Company, or to any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees.

Over-allotment Option

- In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Overall Coordinators (for themselves and on behalf of the Capital Market Intermediaries and the International Underwriters), at any time from the Listing Date until Saturday, January 14, 2023, being the 30th day from the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to a 1,487,800 additional Offer Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocations in the International Offering. If the Over-allotment Option is exercised in full, the additional Offer Shares to be issued pursuant thereto will represent approximately 1.49% of the enlarged total Shares in issue immediately following the completion of the Global Offering and the full exercise of the Over-allotment Option.

- There has been an over-allocation of 1,487,800 Shares in the International Offering and such over-allocation will be settled using Shares to be borrowed under the Stock Borrowing Agreement between Lucky Seven and Morgan Stanley & Co. International plc. Such borrowed Shares will be settled by exercising the Over-allotment Option in full or in part, or by making purchases in the secondary market at prices that do not exceed the Offer Price, or by a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange’s website at www.hkexnews.hk and the Company’s website at www.medbankshealthtech.com. As at the date of this announcement, the Over-allotment Option has not been exercised.

Lock-up Obligations

- The Company, the Single Largest Group of Shareholders, all the other existing Shareholders and the Employee Shareholding Platforms are subject to certain lock-up obligations as set out in the paragraph headed “Lock-up Obligations” in this announcement.

Results of Allocations

- The level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares are published on the Company’s website at www.medbankshealthtech.com and the website of the Stock Exchange at www.hkexnews.hk on Thursday, December 22, 2022.
- The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration/certificate of incorporation numbers of successful applicants under the Hong Kong Public Offering will be available at the times and dates and in the manner specified below:
 - (i) in the announcement to be posted on the Company’s website at www.medbankshealthtech.com and the Stock Exchange’s website at www.hkexnews.hk by no later than Thursday, December 22, 2022;
 - (ii) from the “IPO Results” function in the **IPO App** or the designated results of allocations website at www.tricor.com.hk/ipo/result or www.hkeipo.hk/IPOResult with a “search by ID function” on a 24 hour basis from 8:00 a.m. on Thursday, December 22, 2022 to 12:00 midnight on Wednesday, December 28, 2022; and
 - (iii) from the results allocation telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Thursday, December 22, 2022 to Thursday, December 29, 2022 (excluding Saturday, Sunday and Hong Kong public holiday)
- This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed “Results of Applications Made by **HK eIPO White Form**” in this announcement refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” in this announcement are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

- Please note that the list of identification document numbers set out in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Hong Kong Offer Shares through their brokers can consult their brokers to enquire about their application results.
- Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed “Results of Applications Made by **HK eIPO White Form**” and “Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS” are redacted and not all details of applications are disclosed in this announcement.

Despatch/Collection of Share Certificates/e-Auto Refund Payment Instructions/Refund Cheques

- Applicants who have applied for 300,000 Hong Kong Offer Shares or more through the **HK eIPO White Form** service and whose application is wholly or partially successful may collect Share certificate(s) (where applicable) in person from the Hong Kong Share Registrar, Tricor Investor Services Limited, at 17/F, Far East Finance Centre, 16 Harcourt Road, Hong Kong, from 9:00 a.m. to 1:00 p.m. on Thursday, December 22, 2022, or any other place or date notified by the Company.
- Applicants being an individual who is eligible for personal collection must not authorize any other person to collect on their behalf. If you are a corporate applicant which is eligible for personal collection, your authorized representative must bear a letter of authorization from your corporation stamped with your corporation’s chop. Both individuals and authorized representatives must produce evidence of identity acceptable to our Hong Kong Share Registrar at the time of collection.
- Applicants who apply for less than 300,000 Hong Kong Offer Shares through the **HK eIPO White Form** service, will have their Share certificate(s) (where applicable) sent to the address specified in their application instructions on or before Thursday, December 22, 2022 by ordinary post and at their own risk.
- Share certificates for Hong Kong Offer Shares allotted to applicants who applied through the **HK eIPO White Form** service, which are either not available for personal collection, or which are available but are not collected in person within the time specified for collection, are expected to be despatched by ordinary post to those entitled to the addresses specified in the relevant applications at their own risk on or before Thursday, December 22, 2022.
- Wholly or partially successful applicants who applied by giving **electronic application instructions** to HKSCC will have their Share certificate(s) issued in the name of HKSCC Nominees Limited and deposited directly into CCASS to be credited to their CCASS Investor Participant stock accounts or the stock accounts of their designated CCASS Participant who gave **electronic application instructions** on their behalf on Thursday, December 22, 2022.
- Applicants who applied through a designated CCASS Participant (other than a CCASS Investor Participant) should check the number of Hong Kong Offer Shares allocated to them with that CCASS Participant.

- Applicants who applied as a CCASS Investor Participant by giving **electronic application instructions** to HKSCC via CCASS may also check the number of Hong Kong Offer Shares allocated to them and the amount of refund monies (if any) payable to them via the CCASS Phone System and the CCASS Internet System (under the procedures contained in HKSCC’s “An Operating Guide for Investor Participants” in effect from time to time). Immediately after the crediting of the Hong Kong Offer Shares to the CCASS Investor Participant stock accounts and the credit of refund monies to the CCASS Investor Participants bank accounts, HKSCC will also make available to the CCASS Investor Participants an activity statement showing the amount of Hong Kong Offer Shares credited to their CCASS Investor Participant stock accounts and the refund amount credited to their respective designated bank accounts (if any).
- For applicants who have applied for the Hong Kong Offer Shares through the **HK eIPO White Form** service and paid the application monies through a single bank account, refund monies (if any) will be despatched to that bank account in the form of e-Auto Refund payment instructions. For applicants who have applied for the Hong Kong Offer Shares through the **HK eIPO White Form** service and paid the application monies through multiple bank accounts, refund monies (if any) will be despatched to the addresses specified in your application instructions in the form of refund cheque(s) in favour of the applicant (or, in the case of joint applications, the first-named applicant) by ordinary post and at their own risk on or before Thursday, December 22, 2022.
- Refund monies (if any) for applicants who applied by giving **electronic application instructions** to HKSCC via CCASS are expected to be credited to the relevant applicants’ designated bank accounts or the designated bank accounts of their broker or custodian on Thursday, December 22, 2022.
- Share certificates will only become valid at 8:00 a.m. on Friday, December 23, 2022, provided that the Global Offering has become unconditional in all respects and neither the Hong Kong Underwriting Agreement nor the International Underwriting Agreement has been terminated in accordance with their respective terms at or before that time. Investors who trade Shares on the basis of publicly available allocation details or prior to the receipt of the Share certificates or prior to the Share certificates becoming valid do so entirely at their own risk.
- No temporary document of title will be issued in respect of the Shares. No receipt will be issued for sums paid on application.

PUBLIC FLOAT

- Immediately after the Global Offering, an aggregate of 291,672,948 Shares or approximately 38.2% of the issued share capital of the Company (assuming the Over-allotment Option is not exercised) will be held in the hands of the public. Hence, the number of Shares in the public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08(1) of the Listing Rules.

- The Directors confirm that (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder (as defined in the Listing Rules) of the Company immediately after the completion of the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the Shares held in public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules. The Directors further confirm that, to the best of their knowledge and information, all placees under the International Offering and their ultimate beneficial owners are not and are independent of any of (a) the core connected persons (as defined in the Listing Rules) of the Company, (b) the directors or existing shareholders of the Company or any of the Company's subsidiaries, or (c) the close associates (as defined in the Listing Rules) of (a) and/or (b) above whether in their own names or through nominees.
- The Directors, to the best of their knowledge and information, confirm that, (i) none of the Offer Shares subscribed by public Shareholders in the Hong Kong Public Offering and placees in the International Offering has been financed directly or indirectly by the Company, any of the Directors, chief executive, the Single Largest Group of Shareholders, substantial Shareholders or existing Shareholders of the Company or any of its subsidiaries or their respective close associates; (ii) none of the public Shareholders in the Hong Kong Public Offering and placees in the International Offering who has subscribed for the Offer Shares is accustomed to taking instructions from the Company, any of the Directors, chief executive, the Single Largest Group of Shareholders, substantial Shareholders or existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of the Offer Shares registered in his/her/its name or otherwise held by him/her/it; and (iii) there is no side agreement or arrangement between the Company, any of the Directors, chief executive, the Single Largest Group of Shareholders, substantial shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates, on one hand, and the public subscribers or the placee who has subscribed for the Offer Shares, on the other hand.

COMMENCEMENT OF DEALINGS

Assuming that the Global Offering becomes unconditional in all respects at or before 8:00 a.m. on Friday, December 23, 2022 (Hong Kong time), dealings in the Shares on the Main Board of the Stock Exchange are expected to commence at 9:00 a.m. on Friday, December 23, 2022 (Hong Kong time). The Shares will be traded in board lots of 200 Shares each. The stock code of the Shares is 0314.

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares.

OFFER PRICE

The Offer Price is HK\$18.60 per Offer Share (exclusive of brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and AFRC transaction levy of 0.00015%).

NET PROCEEDS FROM THE GLOBAL OFFERING

Based on the Offer Price of HK\$18.60 per Offer Share, the net proceeds from the Global Offering to be received by the Company, after deduction of underwriting commissions and other estimated expenses payable by the Company in connection with the Global Offering, are estimated to be approximately HK\$120.4 million (assuming the Over-allotment Option is not exercised).

The Company intends to apply the net proceeds as follows:

- (i) approximately 87% of the net proceeds, or approximately HK\$104.8 million, is expected to be used for business expansion, including:
 - (a) approximately 35% of the net proceeds, or approximately HK\$42.2 million, for further expansion of the Company's Specialty Pharmacy Business;
 - (b) approximately 28% of the net proceeds, or approximately HK\$33.7 million, for further expansion of the Company's Physician Research Assistance business;
 - (c) approximately 24% of the net proceeds, or approximately HK\$28.9 million, for further expansion of the Company's Health Insurance Services business; and
- (ii) approximately 13% of the net proceeds, or approximately HK\$15.6 million, is expected to be used for our technology research and development as well as technology infrastructure enhancement.

If the Over-allotment Option is exercised in full, the Company will receive additional net proceeds of approximately HK\$26.5 million for 1,487,800 additional Offer Shares to be issued and allotted upon the exercise of the Over-allotment Option. In the event that the Over-allotment Option is exercised in full, the Company intends to adjust its allocation of the net proceeds for the above purposes on a pro rata basis. For further information, please refer to the section headed "Future Plans and Use of Proceeds" in the Prospectus for details.

APPLICATIONS AND INDICATIONS OF INTEREST RECEIVED UNDER THE HONG KONG PUBLIC OFFERING

The Hong Kong Offer Shares initially offered under the Hong Kong Public Offering have been significantly over-subscribed. A total of 7,588 valid applications have been received under the Hong Kong Public Offering through the **HK eIPO White Form** service and the **CCASS EIPO** service for a total of 8,203,200 Hong Kong Offer Shares, representing approximately 8.27 times of the total number of 992,000 Offer Shares initially available for subscription under the Hong Kong Public Offering, among which:

- 7,586 valid applications for a total of 7,603,200 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount, based on the Offer Price of HK\$18.60 per Offer Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%), of HK\$5,000,000 or less (equivalent to approximately 15.33 times of the 496,000 Shares initially available for allocation in pool A of the Hong Kong Public Offering); and
- 2 valid applications for a total of 600,000 Hong Kong Offer Shares were for the Hong Kong Public Offering with an aggregate subscription amount, based on the Offer Price of HK\$18.60 per Offer Share (excluding brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and Stock Exchange trading fee of 0.005%), of more than HK\$5,000,000 (equivalent to approximately 1.21 times of the 496,000 Shares initially available for allocation in pool B of the Hong Kong Public Offering).

No application has been rejected due to dishonored payments. No application has been rejected due to invalid application. No multiple or suspected multiple application has been identified and rejected. No application for more than 496,000 Hong Kong Offer Shares (being 50% of the 992,000 Hong Kong Offer Shares initially available under the Hong Kong Public Offering) has been identified.

As the over-subscription in the Hong Kong Public Offering is less than 15 times, no reallocation of Offer Shares as described in the paragraph headed “Structure of the Global Offering — The Hong Kong Public Offering — Reallocation” in the Prospectus has been effected from the International Offering to the Hong Kong Public Offering. The final number of Offer Shares under the Hong Kong Public Offering is 992,000 Offer Shares, representing approximately 10% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option), and being allocated to 2,100 successful applicants under the Hong Kong Public Offering, among which 1,925 applicants (representing approximately 91.67% of the 2,100 Shareholders who were allocated the Offer Shares under the Hong Kong Public Offering) have been allocated one board lot of Offer Shares totalling 385,000 Shares (representing approximately 38.81% of the total Offer Shares under the Hong Kong Public Offering).

The Hong Kong Offer Shares offered in the Hong Kong Public Offering were conditionally allocated on the basis set out in the paragraph headed “Basis of Allocation under the Hong Kong Public Offering” below.

INTERNATIONAL OFFERING

The Offer Shares initially offered under the International Offering were slightly over-subscribed. A total of 12,591,107 Offer Shares under the International Offering have been subscribed, representing approximately 1.41 times of the total number of 8,927,400 Offer Shares initially available under the International Offering. The final number of Offer Shares allocated to the places under the International Offering is 8,927,400 Offer Shares, representing approximately 90% of the total number of Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

There has been an over-allocation of 1,487,800 Offer Shares in the International Offering and there are a total of 124 places under the International Offering, among which (i) 118 places have been allotted five or fewer board lots of Offer Shares totalling 38,400 Offer Shares; (ii) 118 places have been allotted four or fewer board lots of Offer Shares totalling 38,400 Offer Shares; (iii) 110 places have been allotted three or fewer board lots of Offer Shares totalling 32,000 Offer Shares; (iv) 92 places have been allotted two or fewer board lots of Offer Shares totalling 21,200 Offer Shares; and (v) 78 places have been allotted one board lot of Offer Shares totalling 15,600 Offer Shares.

The International Offering is in compliance with the Placing Guidelines. None of the Joint Sponsors, the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters, the Capital Market Intermediaries and their respective affiliated companies and connected clients of the lead broker or of any distributors (as defined in the Placing Guidelines) has taken up any Offer Shares for its own benefit under the Global Offering.

The Directors confirm that, to the best of their knowledge and information, no Offer Shares under the International Offering placed by or through the Overall Coordinators, the Joint Global Coordinators, the Joint Bookrunners, the Joint Lead Managers, the Underwriters or the Capital Market Intermediaries under the Global Offering have been placed with any core connected person (as defined in the Listing Rules) of the Company, or to any connected clients (as set out in paragraph 5(1) of the Placing Guidelines), or persons set out in paragraph 5(2) of the Placing Guidelines, whether in their own names or through nominees.

Over-allotment Option

In connection with the Global Offering, the Company has granted the Over-allotment Option to the International Underwriters, exercisable by the Overall Coordinators (for themselves and on behalf of the Capital Market Intermediaries and the International Underwriters), at any time from the Listing Date until Saturday, January 14, 2023, being the 30th day from the last day for lodging applications under the Hong Kong Public Offering, to require the Company to allot and issue up to a 1,487,800 additional Offer Shares, representing not more than 15% of the total number of Offer Shares initially available under the Global Offering, at the Offer Price to cover over-allocations in the International Offering. If the Over-allotment Option is exercised in full, the additional Offer Shares to be issued pursuant thereto will represent approximately 1.49% of the enlarged total Shares in issue immediately following the completion of the Global Offering and the full exercise of the Over-allotment Option.

There has been an over-allocation of 1,487,800 Shares in the International Offering and such over-allocation will be settled using Shares to be borrowed under the Stock Borrowing Agreement between Lucky Seven and Morgan Stanley & Co. International plc. Such borrowed Shares will be settled by exercising the Over-allotment Option in full or in part, or by making purchases in the secondary market at prices that do not exceed the Offer Price, or by a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website at www.hkexnews.hk and the Company's website at www.medbankshealthtech.com. As at the date of this announcement, the Over-allotment Option has not been exercised.

LOCK-UP OBLIGATIONS

The Company, the Single Largest Group of Shareholders and all the other existing Shareholders are subject to certain lock-up undertakings (the “**Lock-up Undertakings**”) in respect of the Shares. The major terms of the Lock-up Undertakings are set out as follows:

Name	Number of Shares subject to the Lock-up Undertakings	Approximate percentage of the total issued share capital of the Company following the completion of the Global Offering which are subject to the Lock-up Undertakings upon Listing ⁽⁴⁾	Last day of the Lock-up Period
The Company⁽¹⁾ <i>(subject to lock-up obligations pursuant to the Listing Rules and the Hong Kong Underwriting Agreement)</i>	N/A	N/A	June 23, 2023 (First Six Month Period)
			December 23, 2023 (Second Six Month Period)
The Single Largest Group of Shareholders⁽²⁾ <i>(subject to lock-up obligations pursuant to the Hong Kong Underwriting Agreement and separate lock-up undertakings in favor of the Company, the Joint Sponsors and the Overall Coordinators)</i>	163,534,455	21.43%	June 23, 2023
Other existing Shareholders⁽³⁾ <i>(subject to lock-up obligations pursuant to their respective lock-up undertakings in favor of the Company, the Joint Sponsors and the Overall Coordinators)</i>	589,571,459	77.27%	June 23, 2023
Total	753,105,914	98.70%	

Notes:

- (1) The Company may not issue or agree to issue or announce its intention to issue Shares or securities of the Company on or before the expiry of the First Six Month Period unless in compliance with the requirements of the Listing Rules; and in the event the Company does so on or before the expiry of the Second Six Month Period, it will take all reasonable steps to ensure it will not create a disorderly or false market in the securities of the Company in breach of the Listing Rules, the SFO or other applicable laws.
- (2) The Single Largest Group of Shareholders include the Founders, Lucky Seven, Simul International Holdings Limited, Spire-succession Limited, Shining-succession Limited and the Employee Incentive Platforms. Save for certain special circumstances as agreed among the parties, without the prior written consent of the Overall Coordinators, the Single Largest Group of Shareholders shall not dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Shares in the First Six Month Period.
- (3) Other existing shareholders include Tencent Mobility, TPP Follow-on, Impresa Fund III Limited Partnership, Eight Roads Investments, ERVC Healthcare Advisors IV L.P., Asia Partners III L.P., F-Prime Capital Partners Healthcare Advisors Fund IV LP, Asia Ventures, ERVC Healthcare, F-Prime Capital, JenCap RX Partners, JenCap RX, ZWC MB Investment Limited, IDG China Venture, IDG China V, CCEIF Bigdata I, Wu Capital Limited, Evolution Special Opportunity Fund I, L.P., Evolution Fund I Co-investment, L.P., FOREBRIGHT VISION LIMITED, INNOVAC INTERNATIONAL LIMITED, Suzhou Yuan Kang Ding Xiang Investment Management Partnership (Limited Partnership), Octagon Investments Master Fund LP, Octagon Private Opportunities Fund LP, HBC Asia Healthcare Opportunities VIII LLC, Grand Bow Global Limited, 3W Healthcare Fund, 3W Global Fund, New Smart, L.P., Sage Partners Alpha 1 L.P., HEALTHY TALENT LIMITED, Fortune Holdings Investment (H.K.) Limited, TAIHECAP LIMITED, Mercury Investment Holdings Limited, Vision Launchpad Holdings Company Limited, Mission Harvest Co., Ltd., Bacta Holdings Limited, Ariel Z Healthcare Co., Ltd., Rosa Care Investment Co., Captain Sean Investment Co., Limited, Robert International Holdings Limited and Jun An Healthcare Co., Limited.
- (4) Assuming the Over-allotment Option is not exercised.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the section headed “Structure of the Global Offering — Conditions of the Global Offering” in the Prospectus, 7,588 valid applications made by the public through the **HK eIPO White Form** service and the **CCASS EIPO** service will be conditionally allocated on the basis set out below:

Pool A			
Number of Shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of Shares applied for
200	4,133	620 out of 4,133 applicants to receive 200 Shares	15.00%
400	1,153	254 out of 1,153 applicants to receive 200 Shares	11.01%
600	190	56 out of 190 applicants to receive 200 Shares	9.82%
800	68	25 out of 68 applicants to receive 200 Shares	9.19%
1,000	1,263	536 out of 1,263 applicants to receive 200 Shares	8.49%
1,200	29	14 out of 29 applicants to receive 200 Shares	8.05%
1,400	28	15 out of 28 applicants to receive 200 Shares	7.65%
1,600	31	18 out of 31 applicants to receive 200 Shares	7.26%
1,800	13	8 out of 13 applicants to receive 200 Shares	6.84%
2,000	383	257 out of 383 applicants to receive 200 Shares	6.71%
3,000	55	200 Shares	6.67%
4,000	24	200 Shares plus 3 out of 24 applicants to receive an additional 200 Shares	5.63%
5,000	53	200 Shares plus 19 out of 53 applicants to receive an additional 200 Shares	5.43%
6,000	21	200 Shares plus 13 out of 21 applicants to receive an additional 200 Shares	5.40%
7,000	8	200 Shares plus 6 out of 8 applicants to receive an additional 200 Shares	5.00%
8,000	12	200 Shares plus 10 out of 12 applicants to receive an additional 200 Shares	4.58%
9,000	3	400 Shares	4.44%
10,000	70	400 Shares plus 14 out of 70 applicants to receive an additional 200 Shares	4.40%

Pool A

Number of Shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of Shares applied for
20,000	21	600 Shares	3.00%
30,000	7	800 Shares	2.67%
40,000	2	1,000 Shares	2.50%
50,000	3	1,200 Shares	2.40%
60,000	5	1,400 Shares	2.33%
70,000	1	1,600 Shares	2.29%
80,000	2	1,800 Shares	2.25%
90,000	1	2,000 Shares	2.22%
100,000	2	2,200 Shares	2.20%
120,000	3	2,600 Shares	2.17%
200,000	2	4,200 Shares	2.10%
Total	<u>7,586</u>	Total number of Pool A successful applicants: 2,098	

Pool B

Number of Shares applied for	Number of valid applications	Basis of allocation/ballot	Approximate percentage allotted of the total number of Shares applied for
300,000	2	248,000 Shares	82.67%
Total	<u>2</u>	Total number of Pool B successful applicants: 2	

The final number of Offer Shares available under the Hong Kong Public Offering is 992,000 Offer Shares, representing approximately 10% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

The final number of Offer Shares available under the International Offering is 8,927,400 Offer Shares, which were allocated in full (subject to the Over-allotment Option), representing approximately 90% of the total number of the Offer Shares initially available under the Global Offering (before any exercise of the Over-allotment Option).

RESULTS OF ALLOCATIONS

The level of indication of interest in the International Offering, the level of applications in the Hong Kong Public Offering and the basis of allocation of the Hong Kong Offer Shares are published on the Company's website at www.medbankshealthtech.com and the website of the Stock Exchange at www.hkexnews.hk on Thursday, December 22, 2022.

The results of allocations and the Hong Kong identity card/passport/Hong Kong business registration/certificate of incorporation numbers of successful applicants under the Hong Kong Public Offering will be available at the times and dates and in the manner specified below:

- (i) in the announcement to be posted on the Company's website at www.medbankshealthtech.com and the Stock Exchange's website at www.hkexnews.hk by no later than 9:00 a.m. on Thursday, December 22, 2022;
- (ii) from the "IPO Results" function in the **IPO App** or the designated results of allocations website at www.tricor.com.hk/ipo/result or www.hkeipo.hk/IPOResult with a "search by ID function" on a 24 hour basis from 8:00 a.m. on Thursday, December 22, 2022 to 12:00 midnight on Wednesday, December 28, 2022; and
- (iii) from the results allocation telephone enquiry line by calling +852 3691 8488 between 9:00 a.m. and 6:00 p.m. from Thursday, December 22, 2022 to Thursday, December 29, 2022 (excluding Saturday, Sunday and Hong Kong public holiday).

This announcement contains a list of identification document numbers. Identification document numbers shown in the section headed "Results of Applications Made by **HK eIPO White Form**" in this announcement refer to Hong Kong identity card numbers/passport numbers/Hong Kong business registration numbers/certificate of incorporation numbers/beneficial owner identification codes (if such applications are made by nominees as agent for the benefit of another person) whereas those displayed in the section headed "Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS" in this announcement are provided by CCASS Participants via CCASS. Therefore, the identification document numbers shown in the two sections are different in nature.

Please note that the list of identification document numbers set out in this announcement may not be a complete list of successful applicants since only successful applicants whose identification document numbers are provided to HKSCC by CCASS Participants are disclosed. Applicants with beneficial names only but not identification document numbers are not disclosed due to personal privacy issue as elaborated below. Applicants who applied for the Hong Kong Offer Shares through their brokers can consult their brokers to enquire about their application results.

Since applications are subject to personal information collection statements, beneficial owner identification codes displayed in the sections headed "Results of Applications Made by **HK eIPO White Form**" and "Results of Applications Made by Giving **Electronic Application Instructions** to HKSCC via CCASS" are redacted and not all details of applications are disclosed in this announcement.

SHAREHOLDING CONCENTRATION ANALYSIS

The tables below set out the analysis of shareholding concentration in the International Offering:

Top 1, 5, 10, 20 and 25 places under the International Offering:

Placee	Number of Shares subscribed for	Number of Shares held upon Listing	Subscription as % of International Offering (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offering (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is not exercised)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	Number of Shares as % of total share capital in issue (assuming no exercise of the Over-allotment Option)	Number of Shares as % of total share capital in issue (assuming the Over-allotment Option is exercised in full)
Top 1	4,082,400	4,082,400	45.7%	39.2%	41.2%	35.8%	0.5%	0.5%
Top 5	10,375,600	10,375,600	116.2%	99.6%	104.6%	91.0%	1.4%	1.4%
Top 10	10,380,000	10,380,000	116.3%	99.7%	104.6%	91.0%	1.4%	1.4%
Top 20	10,386,800	10,386,800	116.3%	99.7%	104.7%	91.1%	1.4%	1.4%
Top 25	10,389,800	10,389,800	116.4%	99.8%	104.7%	91.1%	1.4%	1.4%

Top 1, 5, 10, 20 and 25 Shareholders of the Company upon Listing:

Shareholder	Number of Shares subscribed for	Number of Shares held upon Listing	Subscription as % of International Offering (assuming no exercise of the Over-allotment Option)	Subscription as % of International Offering (assuming the Over-allotment Option is exercised in full)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is not exercised)	Subscription as % of total Offer Shares (assuming the Over-allotment Option is exercised in full)	Number of Shares as % of total share capital in issue (assuming no exercise of the Over-allotment Option)	Number of Shares as % of total share capital in issue (assuming the Over-allotment Option is exercised in full)
Top 1	—	209,119,356	—	—	—	—	27.4%	27.4%
Top 5	—	556,396,197	—	—	—	—	72.9%	72.8%
Top 10	—	661,408,121	—	—	—	—	86.7%	86.5%
Top 20	—	732,046,672	—	—	—	—	95.9%	95.8%
Top 25	7,572,400	751,740,779	84.8%	72.7%	76.3%	66.4%	98.5%	98.3%

In view of the high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded, and should exercise extreme caution when dealing in the Shares.